Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

NCT00349518 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: Dasatinib

Sponsor

Bristol-Myers Squibb